New hope for cerebral palsy: drug may tame involuntary movements

NCT ID NCT05206513

Completed Symptom relief Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called valbenazine to see if it can reduce jerky, uncontrolled movements (chorea) in people with cerebral palsy. The trial included 86 children and adults whose medical condition was stable. Participants received either valbenazine or a placebo for 14 weeks, and researchers measured changes in movement severity using standard rating scales.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Athetosis cerebral palsy choreatic disease Dyskinesias Dystonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CEREBRAL PALSY DYSKINESIA

Contacts and locations

Show contact details

Locations

Neurocrine Clinical Site

San Diego, California, 92123, United States
Neurocrine Clinical Site

Aurora, Colorado, 80045, United States
Neurocrine Clinical Site

Stamford, Connecticut, 06905, United States
Neurocrine Clinical Site

Gulf Breeze, Florida, 32561, United States
Neurocrine Clinical Site

Miami, Florida, 33155, United States
Neurocrine Clinical Site

Orlando, Florida, 32806, United States
Neurocrine Clinical Site

Chicago, Illinois, 60611, United States
Neurocrine Clinical Site

Baltimore, Maryland, 21205, United States
Neurocrine Clinical Site

Boston, Massachusetts, 02115, United States
Neurocrine Clinical Site

Farmington Hills, Michigan, 48334, United States
Neurocrine Clinical Site

Saint Paul, Minnesota, 55101, United States
Neurocrine Clinical Site

New York, New York, 10003, United States
Neurocrine Clinical Site

Cincinnati, Ohio, 45229, United States
Neurocrine Clinical Site

Columbus, Ohio, 43205, United States
Neurocrine Clinical Site

Oklahoma City, Oklahoma, 73120, United States
Neurocrine Clinical Site

Portland, Oregon, 97239, United States
Neurocrine Clinical Site

Dallas, Texas, 75390-8857, United States
Neurocrine Clinical Site

Fort Worth, Texas, 76104, United States
Neurocrine Clinical Site

Houston, Texas, 77030, United States
Neurocrine Clinical Site

Buenos Aires, C1060AAF, Argentina
Neurocrine Clinical Site

Buenos Aires, C1425EFD, Argentina
Neurocrine Clinical Site

Brussels, 1200, Belgium
Neurocrine Clinical Site

Brasília, 70684-831, Brazil
Neurocrine Clinical Site

Curitiba, 80250-060, Brazil
Neurocrine Clinical Site

Porto Alegre, 90035-001, Brazil
Neurocrine Clinical Site

Porto Alegre, 90050-170, Brazil
Neurocrine Clinical Site

Ẕerifin, 7030000, Israel
Neurocrine Clinical Site

Calambrone, 56128, Italy
Neurocrine Clinical Site

Milan, 3. 20162, Italy
Neurocrine Clinical Site

Aguascalientes, Mexico
Neurocrine Clinical Site

Gdansk, 80-389, Poland
Neurocrine Clinical Site

Krakow, 30-539, Poland
Neurocrine Clinical Site

Oświęcim, 32-600, Poland
Neurocrine Clinical Site

Lisbon, 1169-045, Portugal
Neurocrine Clinical Site

Lisbon, 1649-035, Portugal
Neurocrine Clinical Site

Porto, 4050-651, Portugal
Neurocrine Clinical Site

Barcelona, 08038, Spain
Neurocrine Clinical Site

Madrid, 28006, Spain